312 related articles for article (PubMed ID: 28210104)
1. Drug resistance in lung cancer.
Shanker M; Willcutts D; Roth JA; Ramesh R
Lung Cancer (Auckl); 2010; 1():23-36. PubMed ID: 28210104
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
5. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
[TBL] [Abstract][Full Text] [Related]
6. Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance.
Gao Y; Shen JK; Milane L; Hornicek FJ; Amiji MM; Duan Z
Curr Med Chem; 2015; 22(11):1335-47. PubMed ID: 25666804
[TBL] [Abstract][Full Text] [Related]
7. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. The challenge of drug resistance in cancer treatment: a current overview.
Nikolaou M; Pavlopoulou A; Georgakilas AG; Kyrodimos E
Clin Exp Metastasis; 2018 Apr; 35(4):309-318. PubMed ID: 29799080
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
12. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
[TBL] [Abstract][Full Text] [Related]
13. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
Rolfo C; Fanale D; Hong DS; Tsimberidou AM; Piha-Paul SA; Pauwels P; Van Meerbeeck JP; Caruso S; Bazan V; Cicero G; Russo A; Giovannetti E
Curr Pharm Biotechnol; 2014; 15(5):475-85. PubMed ID: 24846062
[TBL] [Abstract][Full Text] [Related]
14. Drug Resistance.
Giaccone G; Pinedo HM
Oncologist; 1996; 1(1 & 2):82-87. PubMed ID: 10387972
[TBL] [Abstract][Full Text] [Related]
15. Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer.
Varghese E; Samuel SM; Líšková A; Samec M; Kubatka P; Büsselberg D
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806533
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
Motadi LR; Misso NL; Dlamini Z; Bhoola KD
Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
[TBL] [Abstract][Full Text] [Related]
17. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
18. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance.
O'Connor R
Curr Cancer Drug Targets; 2009 May; 9(3):273-80. PubMed ID: 19442048
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
20. Targeting apoptotic signaling pathways in human lung cancer.
Han SW; Roman J
Curr Cancer Drug Targets; 2010 Sep; 10(6):566-74. PubMed ID: 20482489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
